Dyne Therapeutics fell 13% on the week to $15.92 — yet options traders are suddenly the most bullish they've been all year.
The options signal is the sharpest thing in this week's data. The put/call ratio collapsed to 1.21, nearly three standard deviations below its 20-day average of 2.27. That's the lowest PCR reading in the past year, against a 52-week low of 0.22 and a high of 2.97. For a stock that has spent most of the past month with a PCR above 2.0, the shift is abrupt. Whether it reflects fresh call buying on a beaten-down name or protective puts rolling off after the selloff, the options market is no longer positioned defensively — which sits in sharp contrast to the price action.
Short interest tells a more familiar story. At 14.8% of free float, the short position has grown a further 2% this week and roughly 4% over the past month. The ORTEX short score holds at 64.5, almost unchanged from the 64 level flagged in last week's note — a level of stability that continues to point to a structural bearish thesis rather than speculative piling-in. The lending market offers no pressure on either side: cost to borrow is just 0.43%, barely moved week-on-week, and availability runs at 649%, meaning there are roughly six-and-a-half shares available to lend for every one already borrowed. New shorts face no friction whatsoever entering this trade.
The Street's view is stretched well above where the stock trades. The mean price target is $38.19 — more than double the current price — though that aggregate includes divergent camps. Evercore ISI trimmed its target by $1 to $33 last week while holding Outperform, and Bernstein nudged its Market Perform target up a dollar to $24, signalling limited near-term conviction even from the sideline. Bulls lean on the FORCE platform's clinical progress in neuromuscular diseases and the pipeline's forward EPS revision trajectory. Bears — and Bernstein's neutral position reflects this — cite the pre-commercial status, dilution risk, and IP exposure. With the stock now trading at a roughly 58% discount to the mean analyst target, the disconnect is wide enough that either the stock has to recover sharply, or targets need another reset.
Institutional ownership adds texture. T. Rowe Price added 13.3 million shares in Q1 2026 to reach 20% of shares outstanding — a significant commitment for a buy-and-hold manager in a pre-revenue biotech. Orbis added roughly 2 million shares in the same period, and Perceptive Advisors increased by nearly 1.2 million. On the other side, Atlas Venture trimmed modestly. The net Q1 institutional picture leans supportive, but the insider picture is less so: the CEO, CFO, CMO, and Chief Commercial Officer all sold small amounts on May 13, and board member Jason Rhodes liquidated roughly $1.5 million across May 5-6. These are not large transactions relative to the float, but the cluster of C-suite sales at prices around $18 — well above where the stock closed Friday — adds a cautious note.
Earnings are due June 5. The last two prints delivered a +4.3% day-one move and a -6.5% day-one move respectively, with wider five-day swings of -6% and +13%. The setup into June 5 is therefore less about whether the quarter lands in line and more about whether the options market's sudden shift toward calls reflects genuine new conviction on the pipeline, or simply reflects the positioning vacuum left by a month-long selloff.
See the live data behind this article on ORTEX.
Open DYN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
